New MRI techniques for cerebrovascular diseases

Gregory W. Albers博士在斯坦福大学医学中心从事以患者为导向的脑血管疾病研究。他的研究成果包括在中风诊断、治疗和预防领域的重大贡献。他还在制定国家脑血管疾病患者临床实践指南方面发挥了重要作用。他是多名年轻中风研究者的成功导师，他的8名学员目前在大学医疗中心担任全职学术职务。Albers博士目前的研究兴趣是评估新的MRI技术的实用性，特别是扩散和灌注MRI，作为急性中风患者的诊断和治疗决策工具。K24奖将使他能够专注于促进几位初级临床研究者的职业发展。该研究计划由三项资助的NIH R01拨款组成。该研究是美国国立卫生研究院资助的一项试点临床试验，旨在确定特定的患者亚组，通过扩散和灌注MRI特征来定义，这些患者在卒中症状出现后3至6小时内接受静脉溶栓治疗可能有良好的反应。该试点试验将提供设计随机临床试验所需的基本数据，以确定卒中患者，选择特定的MRI标准，是否可以从卒中发作后3小时以上的静脉溶栓治疗中获益。诊断试验是一项为期4年、由NIH资助的单中心试验，旨在确定扩散和灌注MRI在出现提示脑缺血症状72小时内的患者中的临床应用。第三个NIH资助的R01拨款将采用复杂的MRI技术来测量急性中风患者的脑灌注，并确定区分临界灌注不足和良性低血凝的定量阈值。一个创新的指导计划提出，将准备年轻的研究人员在临床研究的职业生涯。这个K24研究项目将扩展Albers博士作为临床研究者的技能，并使他成为一个更有效的导师。

DESCRIPTION (provided by applicant): Dr. Gregory W. Albers' career focus has been patient-oriented research in cerebrovascular disease at Stanford University Medical Center. His research accomplishments include significant contributions to the fields of stroke diagnosis, treatment and prevention. He has also played a major role in developing national clinical practice guidelines for patients with cerebrovascular disease. He has been a successful mentor for multiple young stroke investigators and eight of his mentees currently hold full-time academic appointments at university medical centers. Dr. Albers' current research interest is evaluating the utility of new MRI techniques, particularly diffusion and perfusion MRI, as diagnostic and therapeutic decision making tools for patients with acute stroke. The K24 Award will allow him to focus his efforts on facilitating the career development of several junior clinical investigators. The research proposal consists of three funded NIH R01 grants. The DEFUSE study is an NIH funded pilot clinical trial grant that aims to identify specific patient subgroups, defined by diffusion and perfusion MRI profiles, who are likely to have a favorable response to intravenous thrombolytic therapy when treated between 3 and 6 hours after stroke symptom onset. This pilot trial will provide essential data needed to design a randomized clinical trial to determine whether stroke patients, selected with specific MRI criteria, can benefit from intravenous thrombolytic therapy beyond 3 hours after stroke onset. The DIAGNOSIS trial is a 4-year, single-center NIH funded trial designed to determine the clinical utility of diffusion and perfusion MRI in patients presenting within 72 hours of the onset of symptoms suggestive of brain ischemia. A third NIH funded R01 grant will employ sophisticated MRI techniques to measure cerebral perfusion in acute stroke patients and determine quantitative thresholds for differentiating critical levels of hypoperfusion from benign oligemia. An innovative mentoring program is proposed that will prepare young investigators for careers in clinical research. This K24 research program will expand Dr. Albers' skills as a clinical investigator and allow him to become a more effective mentor.